Description
Palbociclib, marketed under the brand name Ibrance, It is an prescription medication that has been approved palbociclib (IBRANCE) for different uses at different times:
February 3, 2015: The FDA granted accelerated approval for palbociclib to treat postmenopausal women with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
March 31, 2017: The FDA granted regular approval for palbociclib.
February 19, 2016: The FDA approved palbociclib in combination with fulvestrant.
April 4, 2019: The FDA expanded the use of palbociclib to treat men with advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer.
What is Ibrance (palbociclib) ?
IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or • fulvestrant in patients with disease progression following endocrine therapy.
Quote From FDA
How to order approved “Ibrance (palbociclib) for capsules” Medicine?
Ibrance (Palbociclib) capsules is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing Ibrance and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
